Scarica l'app Stockscreener
1.73
7.98%
-0.15
Dopo l'orario di chiusura:
1.80
0.07
+4.05%
Precedente Chiudi:
$1.88
Aprire:
$1.86
Volume 24 ore:
229.35K
Relative Volume:
0.03
Capitalizzazione di mercato:
$7.85M
Reddito:
$6.16M
Utile/perdita netta:
$-14.91M
Rapporto P/E:
-0.1621
EPS:
-10.6693
Flusso di cassa netto:
$-9.39M
1 W Prestazione:
+3.59%
1M Prestazione:
-14.36%
6M Prestazione:
+6.13%
1 anno Prestazione:
-79.51%
Intervallo 1D:
$1.72
$2.05
Intervallo di 1 settimana:
$1.6007
$2.175
Portata 52W:
$0.693
$13.80
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.73 | 8.53M | 6.16M | -14.91M | -9.39M | -10.67 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
bioAffinity Technologies Stock Draws Fresh Attention From Traders - Bez Kabli
BIAF News | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - BioSpace
bioAffinity Showcases CyPath Lung in Upcoming Clinical Webinar - TipRanks
bioAffinity webinar to showcase CyPath Lung's role in early-stage lung cancer detection - TradingView
bioAffinity Technologies (BIAF) spotlights CyPath Lung test in SAB lung cancer webinar - Stock Titan
BIAF Stock Chart | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
BIAF Q3 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentManagement Guidance Update - thelegaladvocate.com
bioAffinity Technologies (BIAFW) Short Interest & Short Float | Updated May 2026 - MarketBeat
bioAffinity receives patent allowance in Mexico for lung test - Investing.com UK
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology - BioSpace
bioAffinity receives patent allowance in Mexico for lung test By Investing.com - Investing.com Nigeria
bioAffinity Technologies notifies Mexico patent allowance for CyPath® Lung flow cytometry method - TradingView
Mexico backs bioAffinity (NASDAQ: BIAF) patent on CyPath Lung test - Stock Titan
bioAffinity Technologies (BIAF) News Flow - Moomoo
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
What's Driving bioAffinity Technologies' Recent Surge - Kavout
Top AIAI (AIAI) Competitors 2026 - MarketBeat
bioAffinity Technologies Inc (BIAF) Stock Price, Quote, News & History - Benzinga
BIAF Stock Price, Quote & Chart | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
bioAffinity Technologies, Inc.Warrant (NQ: BIAFW - FinancialContent
bioAffinity (BIAF) registers 497,483 resale shares, includes 365,603 warrants - Stock Titan
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - The Globe and Mail
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan
bioAffinity reports 300% jump in lung test sales in April - Investing.com UK
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Ye - PharmiWeb.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - 01net
bioAffinity Technologies Reports Record 300% Growth in CyPath® Lung Diagnostic Test Sales in April 2026 - Minichart
bioAffinity CyPath Lung Test Sales Surge Sharply - TipRanks
TradingKey - TradingKey
bioAffinity reports 300% jump in lung test sales in April By Investing.com - Investing.com Australia
bioAffinity Reports Record Monthly CyPath Lung Unit Sales, April Up Nearly 300% - TradingView
Record CyPath Lung growth at bioAffinity (NASDAQ: BIAF) with April unit sales up nearly 300% - Stock Titan
bioAffinity Technologies, Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
bioAffinity Technologies reports net loss of USD 3.6M in Q1 2026 - Medical Buyer
bioAffinity Technologies, Inc. 1Q 2026: Revenue $1.35M, EPS $(0.81) — 10-Q Summary - TradingView
BioAffinity Technologies : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
BIAFW bioAffinity reports quarterly results with no revenue or earnings data disclosed; investors await further details.Estimate Uncertainty - thelegaladvocate.com
Q1 2026 loss deepens at bioAffinity Technologies (NASDAQ: BIAF) - Stock Titan
bioAffinity Technologies Releases Q1 2026 Financial Results - AlphaStreet
BIAF | bioAffinity Technologies, Inc. Common Insider Trading - Quiver Quantitative
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - BioSpace
Bioaffinity Technologies IncQ1 2026 net loss $3.6 million or $0.81 per share - marketscreener.com
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.13%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):